The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients
Christopher Schneider(Medical University of Graz), Peter P. Rainer(Tirol Kliniken)
Cited by 32
Related Papers
Nicotinamide for the treatment of heart failure with preserved ejection fraction
|Science Translational Medicine|2021|207
Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity
|Circulation|2022|106
Immune checkpoint inhibitor-associated myocarditis: a novel risk score
|European Heart Journal|2025|34